Drug-Device Combination Products Market by Product (Antimicrobial Catheters, Drug Eluting Stents, Infusion Pumps), Application (Antimicrobial Application, Cancer Treatment, Cardiovascular Disorder), End-user - Global Forecast 2024-2030

Drug-Device Combination Products Market by Product (Antimicrobial Catheters, Drug Eluting Stents, Infusion Pumps), Application (Antimicrobial Application, Cancer Treatment, Cardiovascular Disorder), End-user - Global Forecast 2024-2030

The Drug-Device Combination Products Market size was estimated at USD 133.95 billion in 2023 and expected to reach USD 144.59 billion in 2024, at a CAGR 8.09% to reach USD 231.05 billion by 2030.

A drug-device combination product is a unique class of healthcare products that combines pharmaceuticals and medical devices in a single unit. These products are designed to provide synergistic therapeutic benefits by integrating the pharmacological action of drugs with the physical performance of devices. The drug-device combination product offers innovative solutions for unmet medical needs or enhances existing therapies. Drug-device combination products deliver better patient outcomes compared to each component administered separately by combining drugs and devices into one product. This is primarily due to drug-targeted delivery at specific sites within the body, which increases efficacy while minimizing side effects or systemic toxicity. Incorporating advanced technologies, including smart sensors in these combination products, enables real-time monitoring and control over drug release profiles, which fosters personalized medicine approaches tailored to individual patient needs. Moreover, the prevalence of chronic diseases, including diabetes and heart ailments, has raised the need for minimally invasive and targeted treatment options. Ongoing efforts by regulatory authorities, including the U.S. FDA, to streamline approval processes for innovative combination products provide a favorable environment for manufacturers. However, complex regulatory frameworks and the high cost of research and development (R&D) activities significantly impede the adoption of drug-device combination products. In addition, manufacturers invest in research and development activities to address unmet clinical needs in areas such as targeted drug delivery systems or bioresorbable implants. Exploring new drug-device combinations to fight antibiotic-resistant infections or enhance cancer therapies is expected to create prospects for developing drug-device combination products.

Regional Insights

In the Americas, there is a growing need for drug-device combination products due to the increasing prevalence of chronic diseases, the aging population, technological advancements, and favorable reimbursement policies. The U.S. Food and Drug Administration (FDA) has been actively involved in approving patents and supporting research initiatives to develop drug-device combination products. In the Asia-Pacific, countries including China, Japan, India, and South Korea focus on cost-effective solutions to address unmet medical needs for their large patient pool suffering from chronic illnesses such as diabetes or cardiovascular diseases. China's National Medical Products Administration (NMPA) released new guidelines on clinical evaluation reports for medical devices promoting advancements in drug-device combination products. In addition, Japan's Pharmaceuticals and Medical Devices (PMD) Act ensures the quality, efficacy, and safety of pharmaceuticals, medical devices, and similar products. European Union countries have witnessed a surge in investment within biotechnology and medical device sectors, improving research activities on drug-device combination products. The European Medicines Agency (EMA) plays a vital role in evaluating these products' safety and efficacy. Major players collaborate with academic institutions to develop innovative solutions catering to specific regional demands. In the Middle East and Africa region, several regional governments focus on investing in healthcare infrastructure development that provides future growth opportunities for developing drug-device combination products.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Drug-Device Combination Products Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Prevalence of chronic disease and emphasis on targeted treatments
Favorable government approvals for various drug-device combination products
Preference for minimally invasive surgeries and use of antimicrobial and drug-eluting stents

Market Restraints

Dosing and operational limitations of drug-device combination products

Market Opportunities

Technological advancements in drug-device combination products
Amalgamation strategies to expand drug-device combination product commercialization

Market Challenges

Regulatory hurdles associated with approval of customized combination products

Market Segmentation Analysis

Product: Increasing use of drug eluting stents and orthopedic combination products in surgical procedures
Application: Emerging need of drug-device combination products for efficient treatment across oncology and cardiovascular disorder

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Drug-Device Combination Products Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Drug-Device Combination Products Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Nemera and Nelson Labs Europe trengthen partnership to offer integrated services to customer

Nemera, a provider of drug delivery device solutions and combination product services, announced strengthening its existing partnership with Nelson Labs Europe, a significant player across the globe in microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. This non-exclusive collaboration allowed Nemera to access extractables & leachables, biocompatibility, microbiology, and chemical testing from Nelson Labs, delivering an integrated service offering to clients for their drug/device combination products and accelerating their market entry. They anticipated a productive collaboration, enhancing their mutual capabilities in providing superior solutions in the medical device and pharmaceutical sectors.

Kindeva and Meridian Combine: Create Leading Drug-Device Combination Product CDMO

Kindeva Drug Delivery and Meridian Medical Technologies completed their merger, resulting in the formation of a global Contract Development and Manufacturing Organization (CDMO) specializing in drug-device combination products. This merger aimed to expand the range of drug delivery capabilities by leveraging expertise and technology across parenteral, inhalation, transdermal, and intradermal administration routes.

Terumo Announces Launch of Drug-Device Combination Product Co-Developed with Kyowa Kirin

Terumo Corporation launched G-Lasta Subcutaneous Injection 3.6 mg BodyPod, a novel drug-device combination product created in collaboration with Kyowa Kirin Co., Ltd. The activated device is attached to the patient's body at the clinic during chemotherapy and automatically administers the drug approximately 27 hours later. The introduction of this advanced drug-device combination product streamlines treatment and reduces patient burden associated with post-chemotherapy visits.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Drug-Device Combination Products Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Drug-Device Combination Products Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Braile Biomédica, Cardinal Health, Inc., CODAN Companies, Cook Group Incorporated, F. Hoffmann-La Roche AG, Fresenius Kabi, ICU Medical, Inc., InfuTronix, InSitu Technologies Inc., Insulet Corporation, JMS North America Corporation, Lepu Medical Technology Company, Medtronic PLC, MicroPort Scientific Corporation, Novartis AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., SOOIL Developments Co., Ltd., Stryker Corporation, Teleflex Incorporated, Terumo Corporation, Viatris Inc., W. L. Gore & Associates Inc., and Zyno Medical.

Market Segmentation & Coverage

This research report categorizes the Drug-Device Combination Products Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Antimicrobial Catheters
Drug Eluting Stents
Infusion Pumps
Inhalers
Orthopedic Combination Products
Photodynamic Therapy Devices
Prefilled Syringes
Transdermal Patches
Wound Care Products
Application
Antimicrobial Application
Cancer Treatment
Cardiovascular Disorder
Diabetes
Respiratory Problem
End-user
Ambulatory Surgery Centers
Home Care Settings
Hospital & Clinic
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year